3-Arylcoumarins as highly potent and selective monoamine oxidase B inhibitors: Which chemical features matter?
MetadataShow full item record
Monoamine oxidase B inhibitory activity is closely regulated by the interaction of the small molecules with the enzyme. It is therefore desirable to use theoretical approaches to design rational methods to develop new molecules to modulate specific interactions with the protein. Here, we report such methods, and we illustrate their successful implementation by studying six synthetized 3-arylcoumarins (71–76) based on them. Monoamine oxidase B inhibition is essential to maintain the balance of dopamine, and one of its major functions is to combat dopamine degradation, a phenomenon linked to Parkinson's disease. In this work, we study small-molecule inhibitors based on the 3-arylcoumarin scaffold and their monoamine oxidase B selective inhibition. We show that 3D-QSAR models, in particular CoMFA and CoMSIA, and molecular docking approaches, enhance the probability to find new interesting inhibitors, avoiding very costly and time-consuming synthesis and biological evaluations. © 2020 Elsevier Inc.
Showing items related by title, author, creator and subject.
Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors (2020) Costas-Lago M.C.; Besada P.; Rodríguez-Enríquez F.; Viña D.; Vilar S.; Uriarte E.; Borges F.; Terán C. (Elsevier Masson SAS, 2017)
Synthesis, biological evaluation, and molecular simulation of chalcones and aurones as selective MAO-B inhibitors (2020) Morales-Camilo N.; Salas C.O.; Sanhueza C.; Espinosa-Bustos C.; Sepúlveda-Boza S.; Reyes-Parada M.; Gonzalez-Nilo F.; Caroli-Rezende M.; Fierro A. (Blackwell Publishing Ltd, 2015)
Discovery and optimization of 3-thiophenylcoumarins as novel agents against Parkinson's disease: Synthesis, in vitro and in vivo studies (2020) Rodríguez-Enríquez F.; Viña D.; Uriarte E.; Fontenla J.A.; Matos M.J. (Academic Press Inc., 2020)